Skip to content

EMBRACE YOUR POWER

Embrace Your Power: A VR Journey to Overcoming Negative Emotions for Romanian Youth

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07148219
Acronym
EYP-VR
Enrollment
300
Registered
2025-08-29
Start date
2025-10-31
Completion date
2027-01-31
Last updated
2025-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullying, Bullying Victimisation, Distress

Keywords

randomized controlled trial, bullying, virtual reality, distress

Brief summary

The goal of this randomized controlled trial is to test the effectiveness of an educational tool, based on virtual reality (VR), for preventing and combating bullying and for improving the emotional well-being of pre-adolescent students. Participants will be allocated to one of two conditions: * (1) intervention group: Embrace your power intervention for combating bullying; * (2) waitlist (inactive control): the control group receives intervention after the study ends. The intervention group will be compared to the control group in terms of peer aggression and victimization (bullying behaviors) and emotional symptoms.

Detailed description

This protocol outlines a cluster, parallel-group, exploratory, randomized controlled trial where participants are randomly allocated to one of the two groups: intervention or control. * The main objective is to implement and assess the effectiveness of the program for combating bullying through virtual reality. The program aims to reduce victimization and bullying behaviors (physical, verbal, and relational aggression) by applying the APRI tool as a result of participating in VR scenarios that simulate these situations and to reduce emotional difficulties and behavioral problems, as well as increase prosocial behavior. * The included classes will serve as the randomization units. Students aged between 10 and 14 years, (5th and 6th grades from middle schools) will participate in the study. The intervention will last 7 weeks, and the two groups will be assessed at (1) pre-intervention (baseline), (2) middle of the intervention (week 3 or 4), and (3) post-intervention. The data analysis will focus on improvement in outcomes between and within groups.

Interventions

BEHAVIORALEmbrace Your Power: A VR Journey to Overcome Negative Emotions

EYP-VR represents a virtual reality (VR) educational tool to combat bullying. Using Meta Quest 3 passthrough technology, the app combines real-world classroom elements with immersive virtual scenarios, enabling safe and interactive experiences that simulate bullying situations but that do not place students in the roles of victims or aggressors but heroes or protectors. The app guides participants through narrative episodes focused on building empathy, practicing assertiveness, and learning conflict resolution techniques. AI-driven characters dynamically respond to students' actions as they engage in puzzles, and sensory feedback (visual, auditory, and haptic) reinforces key socio-emotional learning outcomes. The program will take place in classrooms during instructional hours. Each session will end with a feedback phase so that the school counselor can manage any issues that interest them.

Sponsors

Remnant Dream SRL
CollaboratorUNKNOWN
University of Bucharest
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Intervention model description

A randomized controlled trial where participants are divided into 2 groups: the intervention group that has access to the virtual reality program for preventing bullying and the inactive control group that receives the intervention after the study ends.

Eligibility

Sex/Gender
ALL
Age
10 Years to 14 Years
Healthy volunteers
Yes

Inclusion criteria

* Students 5th and 6th grade * Students whose parents have given their consent and who have also agreed to participate in the program

Exclusion criteria

* Medical problems that have VR-based procedures as contraindicated because they can induce dizziness, seizures, nausea: 1. epilepsy 2. presence of seizures 3. severe motion sickness- vestibular disorders 4. significant vision problems that would interfere with the use of the headset 5. severe migraines triggered by exposure to screens * Neurodevelopmental disorders 1. Autism spectrum disorder- level 3 of severity or sensory processing disorders 2. ADHD, if hyperactivity would prevent the student from staying in the exercise for longer * Points a) and b) do not represent automatic

Design outcomes

Primary

MeasureTime frameDescription
Bullying behaviorsPre-intervention (baseline), middle intervention, post-intervention (week 7)Bullying behaviors will be measured using the Adolescent Peer Relations Instrument (APRI) -C2. The instrument encompasses bullying victimization, perpetration, and bystander experiences. APRI represents a psychometric tool that measures teens' experiences with bullying and victimization through 36 items rated on a 6-point Likert scale (1= never, 6= every day).

Secondary

MeasureTime frameDescription
Emotional symptomsPre-intervention (baseline), middle intervention, post-intervention (week 7)Emotional distress will be assessed using the Emotional Symptoms subscale from the Strengths and Difficulties Questionnaire - SDQ (Romanian self-report). The instrument consists of 25 items, and 5 items are representative of emotional symptoms. Items are rated on a 3-point Likert scale where 1= untrue and 3= certainly true.

Other

MeasureTime frameDescription
Strengths and DifficultiesPre-intervention (baseline), middle intervention, post-intervention (week 7)The other subscales from the Strengths and Difficulties Questionnaire (SDQ) will be used to measure conduct problems (5 items), hyperactivity/inattention (5 items), peer relationship problems (5 items) and prosocial behavior (5 items). Items are measured on a 3-point Likert scale where 1= untrue and 5= certainly true.

Countries

Romania

Contacts

Primary ContactCezar Giosan, PhD
giosan@outlook.com+40730908050

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026